Viveve Medical (VIVE) and The Competition Head-To-Head Analysis
Viveve Medical (NASDAQ: VIVE) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its peers? We will compare Viveve Medical to similar companies based on the strength of its risk, profitability, valuation, earnings, analyst recommendations, dividends and institutional ownership.
Valuation and Earnings
This table compares Viveve Medical and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Viveve Medical||$10.42 million||-$25.39 million||-2.62|
|Viveve Medical Competitors||$2.06 billion||$438.96 million||-75.15|
Viveve Medical’s peers have higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
65.6% of Viveve Medical shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 35.1% of Viveve Medical shares are owned by insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Viveve Medical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Viveve Medical Competitors||-328.60%||-36.03%||-12.66%|
This is a breakdown of recent ratings and target prices for Viveve Medical and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Viveve Medical Competitors||263||1837||3294||105||2.59|
Viveve Medical currently has a consensus target price of $10.50, indicating a potential upside of 88.85%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.28%. Given Viveve Medical’s stronger consensus rating and higher probable upside, research analysts plainly believe Viveve Medical is more favorable than its peers.
Volatility & Risk
Viveve Medical has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500. Comparatively, Viveve Medical’s peers have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.
Viveve Medical Company Profile
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.